House Bill No. by Representative Bamburg aims to enhance transparency in prescription drug pricing by requiring that educational or marketing materials directed at healthcare providers include specific price information. The bill enacts Part VI-C of Chapter 20 of Title 37 of the Louisiana Revised Statutes, specifically R.S. 37:1742.11. It mandates that any person providing such materials must disclose the average wholesale acquisition cost for a thirty-day supply of the drug, or for a shorter duration if applicable, along with the date the materials were prepared. Additionally, the materials must inform providers of any available biosimilars or generic alternatives for the same disease state.

The bill establishes that failure to comply with these requirements will be considered a prohibited practice under the Unfair Trade Practices and Consumer Protection Law, subjecting violators to enforcement actions as outlined in that law. This legislative measure is intended to empower healthcare providers with essential pricing information, ultimately benefiting patients by promoting informed prescribing practices.